The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and ...

Significant interaction seen for full psoriasis polygenic risk score with waist-to-hip ratio on psoriasis risk.

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.